Hypertension and nephrology

[Diagnosis of hypertension and target levels in mirror of the newest recommendations]


APRIL 20, 2015

Hypertension and nephrology - 2015;19(02)

[In the past year, many societies published new recommendations in the field of hypertension. The European Society of Hypertension and the European Society of Cardiology (ESH/ESC) published a comprehensive guideline in July 2013, providing an elaborate description of the diagnosis of hypertension. The clinical practice guideline of the American Society of Hypertension and the International Society of Hy per - tension (ASH/ISH) contains a brief set of recommendations, and explains the diagnostic approach to hypertension in a less detailed manner. The Eighth Joint National Committee (JNC8) focuses on certain aspects of hypertension using rigorous evidence- based methodology. This article displays some of the corresponding and disparate recommendations of the three guidelines.]



Further articles in this publication

Hypertension and nephrology

[DASH Diet on its Own or in Combination with Activity and Weight Loss: the Evaluation of Effectiveness in Non-Medicated Hypertension (Grade I) Patients on Blood Pressure and Cardiovascular Biomarkers: the ENCORE Study]


Hypertension and nephrology

[Therapy of hypertension in mirror of the newest recommendations]


[Hypertension guidelines published by various societies in the previous year follow two distinct trends regarding recommendations about treatment. The European Society of Hypertension and the European Society of Cardiology (ESH/ESC) gives the clinician free hand to select the antihypertensive drug, mentioning the optimal treatment regime for various associated clinical conditions. Guidelines published by the American Society of Hypertension and the International Society of Hypertension (ASH/ISH) or by the Eighth Joint National Committee (JNC8) are far less permissive, recommend the first drug of choice from a narrower circle of antihypertensive agents and describe the initiation and escalation of therapy in algorithms. This article displays some of the corresponding and disparate recommendations of the three guidelines.]

Hypertension and nephrology

[Report on the 3rd Szeged Hypertension Day]


Hypertension and nephrology

[Tubulointerstitial nephritis and uveitis syndrome]


[Tubulointerstitial nephritis and uveitis (TINU) syndrome is a rare and underdiagnosed oculorenal disorder that is characterized by the development of acute tubulointerstitial nephritis and uveitis. The median age of onset is 15 years, but it may occur at any age. There is a female predominance. Uveitis might occur before, after, and also concomitantly with tubulointerstitial nephritis. The symptoms are typically non-specific, including fever, loss of appetite, weight loss, nausea and vomiting, weakness, abdominal pain, arthralgias and myalgias. Laboratory findings reveal an acute impairment of renal function, anaemia and elevated inflammatory parameters. Urinary findings are consistent with tubulointerstitial nephritis including subnephrotic proteinuria, sterile leucocyturia, microhaematuria, and tubular dysfunction (e.g. normoglycemic glycosuria). The prognosis appears to be good, especially in children. Persistent renal dysfunction only develops in a small proportion of cases. In this paper, we present the case of a 39-year-old female patient with TINU syndrome, and review the literature.]

Hypertension and nephrology

[A Brief History of Hypertension. 3. The Development of Blood Pressure Measurement]

BARNA István

All articles in the issue

Related contents

Hypertension and nephrology

[Management of hypertensive crises]

JÁRAI Zoltán, ÁCS Tamás, FARSANG Csaba

Hypertension and nephrology

[Measurement and value of blood pressure variability in increasing the number of patients reaching target blood pressure goal in hypertension]

KÉKES Ede, JÁRAI Zoltán, PAKSY András, KISS István

[The authors evaluate the indexes and their usefulness of the short term (ABPM), medium and long term measurement of the blood pressure variability in the care phase of the hypertensive population in Hungary by using a one-year multicentre prospective observational study. The population was split into two parts: in the active group, telemedicine tools were used to maximize the patientphysician relationship and patient education, their own activity. In the non-active group, traditional care took place. Among these, 6725, 18-64 years and 1005, 65 + years of hypertensive patients were analysed. At the start of the study, ABPM was performed in 243 cases. 1407 diabetic hypertensive patients were compared to non-diabetic patients. They have analysed previous international and domestic experiences. In the present study, the reduction of systolic and diastolic blood pressure variability was successful and significant in the 18-64 age group during the whole patients’ care phase, but a larger systolic variability reduction in the active group was achieved. In the 65+s, the systolic variability reduction was found to be significant, but the variability indexes in the active group were also smaller. In the 65+s, the diastolic variability did not change significantly in either group. In diabetic hypertension, variability indices were only reduced to 12 months. It could be clearly demonstrated that a high-level physician patient relationship has a beneficial effect on blood pressure fluctuation in hypertensive patients.]

Lege Artis Medicinae


NAGY Viktor

[There are several evidence-based recommendations for the antihypertensive treatment of diabetic patients. The treatment should be chosen in such way that the target blood pressure (<130/80 Hgmm) is reached and the risk of target organ failure and cardiovascular mortality is minimized. Based on the studies, it seems that the angiotensin converting enzyme II receptor blockers and low-dose thiazide diuretics, along with their combinations can be recommended as first-line treatment in diabetes mellitus. Beta-receptor blockers and calciumchannel inhibitors are more effective than placebo and may be can be combined with angiotensin converting enzyme inhibitors, angiotensin converting enzyme II blockers and diuretics. This is important, because the effective antihypertensive treatment and the prevention of complications in diabetic patients can rarely be achieved with monotherapy only.]

Hypertension and nephrology

[Treatment of high blood pressure in praxis and beyond. Hypertension praxis model]

ÁDÁM Ágnes

[Author presents a hypertension care model in the general praxis. Hypertensive patients and those with diabetes, hyperlipidemia and obesity, OSAS and the therapeutic results with these care model system for three years was analysed. The target blood pressure was achieved in a great rate in all patient’s groups. the elements of therapeutic success was analysed.]

Hypertension and nephrology

[Role of β-blockers, especially carvedilol in the treatment of hypertension]

PÁLL Dénes, MARODA László, ZRÍNYI Miklós

[Changes in hypertension guidelines in the past years have affected the clinical thinking about β-blockers. Authors reviewed the development of β-blockers emphasizing the differences across various active pharmaceutical agents. Different hemodynamic and metabolic effects are being discussed in details for the third ge - neration vasodilatator carvedilol. Carvedilol has no effect on cardiac output but decreases peripheral vascular resistance which results in lower blood pressure values. However, carvedilol, opposite to unfavorable effects of traditional β-blockers, has a neutral impact on both carbohydrate and lipid metabolisms. Its more advanced cardiac effects include decreased left ventricular hypertrophy and increased coronary flow reserve. Vasodilatator type β-blockers (carvedilol, nebivolol) are indicated in the combi - nation treatment of hypertension, especially when the patient has heart failure, coronary disease or suffered from a previous heart attack.]